| |
Teams have limited resources to define and implement new business solutions. IQVIA Health Business Analysts are uniquely positioned to solve these challenges across a variety of commercial operations domains. Read the fact sheet to learn more.
|
|
| By Conor Hale It’s one thing to design an experiment that succeeds in the lab. It’s another to design one that works in every lab—and every hospital, every doctor’s office, every home, or in the hands of every surgeon, every nurse and every patient. |
|
|
|
By Kevin Dunleavy Less than three months after completing its $43 billion acquisition of Seagen, Pfizer has confirmed a report that it is shutting down construction of a $350 million manufacturing facility in Everett, Washington. The decision will affect 120 employees working on the initial setup of the site, the company said. |
By Max Bayer Biogen's executive vice president and head of corporate development, Adam Keeney, Ph.D., says the company is interested in tacking on additional rare disease drugs at a smaller price than the Reata acquisition. The focus is now on clinical-stage products compared to buying commercial medicines. |
By Max Bayer Moderna is laying off some employees within its manufacturing unit after shaving COVID production costs. The company previously disclosed plans to rightsize its COVID vaccine production footprint. |
By Max Bayer Apparently C4 Therapeutics' protein degradation tech brings all the Mercks to the yard. The Massachusetts biotech has signed on Merck KGaA in a $740 million biobucks partnership to find two degraders for cancer. |
By Kevin Dunleavy Less than three weeks after a Texas judge tossed a lawsuit by industry lobbying group PhRMA that challenged the constitutionality of the Inflation Reduction Act, a federal court in Delaware has done the same with a similar action brought by AstraZeneca. |
By Max Bayer Gilead and Merus are linking up in a new research and licensing deal for the latter's trispecific T-cell engages. Gilead is handing over $56 million in upfront cash plus a $25 million equity investment to jumpstart the deal. |
By Nick Paul Taylor Teva has found out the hard way about the scope of the U.K. advertising code. The drugmaker refuted complaints about the alleged promotion of its drugs in an earned media article, only for the panel to rule it responsible for the content and find it guilty of discrediting the pharma industry. |
By Conor Hale Baxter disclosed that its long-gestating plans to spin out its dialysis care operations into an independent company may be dropped, in favor of a sale later this year. |
By Zoey Becker The reorganization program is called "Evonik Tailor Made" and looks to save around €400 million annually by 2026. |
By Helen Floersh New data suggest Vivani’s miniature exenatide implant, NPM-115, works as well as Novo Nordisk’s Wegovy and Ozempic for weight loss in mice. The implant delivers high doses of exenatide, a GLP-1 receptor agonist commercialized by AstraZeneca as Bydureon for treating Type 2 diabetes. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Wednesday, March 20, 2024 | 1pm ET / 10am PT Join us as we take a deep dive into how to plan and manage the evolution of your eTMF. This webinar will feature case studies from leading industry organizations, the latest best practices and TMF trends, data standards and migration considerations, and more. Register now.
|
|
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| WhitepaperAmidst rapid change, it is crucial for specialty distributors to maintain a balance of service and quality for manufacturers, ensuring neither is sacrificed. Explore why this balance is paramount for success in the evolving landscape of pharma. Sponsored by: BioCare |
| |
|
